Target Price | $11.22 |
Price | $3.79 |
Potential |
196.04%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target BioXcel Therapeutics, Inc. 2026 .
The average BioXcel Therapeutics, Inc. target price is $11.22.
This is
196.04%
register free of charge
$69.30
1,728.50%
register free of charge
$1.01
73.35%
register free of charge
|
|
A rating was issued by 12 analysts: 9 Analysts recommend BioXcel Therapeutics, Inc. to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the BioXcel Therapeutics, Inc. stock has an average upside potential 2026 of
196.04%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 2.27 | 0.81 |
64.49% | 64.25% | |
EBITDA Margin | -2,841.41% | -5,623.85% |
76.56% | 97.92% | |
Net Margin | -2,625.55% | -4,415.55% |
79.76% | 68.18% |
8 Analysts have issued a sales forecast BioXcel Therapeutics, Inc. 2025 . The average BioXcel Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an BioXcel Therapeutics, Inc. EBITDA forecast 2025. The average BioXcel Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 BioXcel Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average BioXcel Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -23.51 | -5.41 |
76.10% | 76.99% | |
P/E | negative | |
EV/Sales | 180.43 |
8 Analysts have issued a BioXcel Therapeutics, Inc. forecast for earnings per share. The average BioXcel Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
BioXcel Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 28 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
LUCID CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Jul 15 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 23 2025 |
Rodman & Renshaw |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 28 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 19 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 15 2025 |
Locked
LUCID CAPITAL MARKETS:
Locked
➜
Locked
|
Jul 15 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 23 2025 |
Locked
Rodman & Renshaw:
Locked
➜
Locked
|
Mar 19 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 30 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.